Abstract
Patients with celiac disease (CD) frequently suffer from iron deficiency anemia (IDA) and may benefit from iron supplementation. However, intolerance to iron sulfate and duodenal atrophy could reduce the efficacy of this supplementation. This study evaluated the efficacy of a new sucrosomial iron formulation in patients with CD. Consecutive patients with CD and IDA were divided into two groups: patients with a known intolerance to iron sulfate were treated with sucrosomial iron (30 mg of iron/day), while those receiving iron supplementation for the first time were assigned to iron sulfate (105 mg of iron/day). Forty-three patients were enrolled (38 females, mean age 49 ± 9 years). After a follow-up of 90 days both groups showed an increase in Hb levels compared to baseline (+10.1% and +16.2% for sucrosomial and sulfate groups, respectively), and a significant improvement in all iron parameters, with no statistical difference between the two groups. Patients treated with sucrosomial iron reported a lower severity of abdominal symptoms, such as abdominal and epigastric pain, abdominal bloating, and constipation, and a higher increase in general well-being (+33% vs. +21%) compared to the iron sulfate group. Sucrosomial iron can be effective in providing iron supplementation in difficult-to-treat populations, such as patients with CD, IDA, and known intolerance to iron sulfate.
| Original language | English |
|---|---|
| Article number | 330 |
| Journal | Nutrients |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 9 2018 |
Fingerprint
Keywords
- Celiac disease
- Iron deficiency anemia
- Iron sulfate
- Sucrosomial iron
ASJC Scopus subject areas
- Food Science
- Nutrition and Dietetics
Cite this
Sucrosomial iron supplementation in anemic patients with celiac disease not tolerating oral ferrous sulfate : A prospective study. / Elli, Luca; Ferretti, Francesca; Branchi, Federica; Tomba, Carolina; Lombardo, Vincenza; Scricciolo, Alice; Doneda, Luisa; Roncoroni, Leda.
In: Nutrients, Vol. 10, No. 3, 330, 09.03.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sucrosomial iron supplementation in anemic patients with celiac disease not tolerating oral ferrous sulfate
T2 - A prospective study
AU - Elli, Luca
AU - Ferretti, Francesca
AU - Branchi, Federica
AU - Tomba, Carolina
AU - Lombardo, Vincenza
AU - Scricciolo, Alice
AU - Doneda, Luisa
AU - Roncoroni, Leda
PY - 2018/3/9
Y1 - 2018/3/9
N2 - Patients with celiac disease (CD) frequently suffer from iron deficiency anemia (IDA) and may benefit from iron supplementation. However, intolerance to iron sulfate and duodenal atrophy could reduce the efficacy of this supplementation. This study evaluated the efficacy of a new sucrosomial iron formulation in patients with CD. Consecutive patients with CD and IDA were divided into two groups: patients with a known intolerance to iron sulfate were treated with sucrosomial iron (30 mg of iron/day), while those receiving iron supplementation for the first time were assigned to iron sulfate (105 mg of iron/day). Forty-three patients were enrolled (38 females, mean age 49 ± 9 years). After a follow-up of 90 days both groups showed an increase in Hb levels compared to baseline (+10.1% and +16.2% for sucrosomial and sulfate groups, respectively), and a significant improvement in all iron parameters, with no statistical difference between the two groups. Patients treated with sucrosomial iron reported a lower severity of abdominal symptoms, such as abdominal and epigastric pain, abdominal bloating, and constipation, and a higher increase in general well-being (+33% vs. +21%) compared to the iron sulfate group. Sucrosomial iron can be effective in providing iron supplementation in difficult-to-treat populations, such as patients with CD, IDA, and known intolerance to iron sulfate.
AB - Patients with celiac disease (CD) frequently suffer from iron deficiency anemia (IDA) and may benefit from iron supplementation. However, intolerance to iron sulfate and duodenal atrophy could reduce the efficacy of this supplementation. This study evaluated the efficacy of a new sucrosomial iron formulation in patients with CD. Consecutive patients with CD and IDA were divided into two groups: patients with a known intolerance to iron sulfate were treated with sucrosomial iron (30 mg of iron/day), while those receiving iron supplementation for the first time were assigned to iron sulfate (105 mg of iron/day). Forty-three patients were enrolled (38 females, mean age 49 ± 9 years). After a follow-up of 90 days both groups showed an increase in Hb levels compared to baseline (+10.1% and +16.2% for sucrosomial and sulfate groups, respectively), and a significant improvement in all iron parameters, with no statistical difference between the two groups. Patients treated with sucrosomial iron reported a lower severity of abdominal symptoms, such as abdominal and epigastric pain, abdominal bloating, and constipation, and a higher increase in general well-being (+33% vs. +21%) compared to the iron sulfate group. Sucrosomial iron can be effective in providing iron supplementation in difficult-to-treat populations, such as patients with CD, IDA, and known intolerance to iron sulfate.
KW - Celiac disease
KW - Iron deficiency anemia
KW - Iron sulfate
KW - Sucrosomial iron
UR - http://www.scopus.com/inward/record.url?scp=85044087307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044087307&partnerID=8YFLogxK
U2 - 10.3390/nu10030330
DO - 10.3390/nu10030330
M3 - Article
AN - SCOPUS:85044087307
VL - 10
JO - Nutrients
JF - Nutrients
SN - 2072-6643
IS - 3
M1 - 330
ER -